Skip to content
Toggle navigation
Sign Up
Contact
Twitter
LinkedIn
Search
Search
About CARB-X
Overview
Global Threat
Our Strategy
Stewardship and Access
Management & Staff
Joint Oversight Board
Advisory Board
Careers
Annual Reports
Boston University
Portfolio
Portfolio Product Developers
Portfolio-Pipeline
CARB-X Graduates
Spotlight on Science
Portfolio Acceleration Tools
Partners
Funding Partners
Global Accelerator Network
Apply
2022-2023 Funding Themes
Omnibus Solicitation
Omnibus Outcomes
Entering Portfolio
Resources
CARB-X Connect
Presentations
Videos
Publications
Education
PD Resources
Fact Sheets
AMR Test Directory
News
CARB-X News
Recommended News
In the News
Antibiotic Resistance
Product Developer News
Events
About CARB-X
Overview
Global Threat
Our Strategy
Stewardship and Access
Management & Staff
Joint Oversight Board
Advisory Board
Careers
Annual Reports
Boston University
Portfolio
Portfolio Product Developers
Portfolio-Pipeline
CARB-X Graduates
Spotlight on Science
Portfolio Acceleration Tools
Partners
Funding Partners
Global Accelerator Network
Apply
Funding Themes
Omnibus Solicitation
Application Process (2022-2023)
Entering Portfolio
Applicant Questions (2019)
Resources
Presentations
Videos
Publications
Education
PD Resources
Fact Sheets
AMR Test Directory
News
CARB-X News
Recommended News
In the News
Antibiotic Resistance
Product Developer News
Events
Contact
Legal
News
Helixbind: FDA Grants HelixBind Breakthrough Device Designation for RaPID Sepsis Test
Helixbind: FDA Grants HelixBind Breakthrough Device Designation for RaPID Sepsis Test
Toggle navigation
Toggle navigation